

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-49. (Cancelled)

50. (New) A lysate obtainable by a process comprising the steps:

(a) inducing necrosis of tumor cells by subjecting the cells to a temperature of at least 45.5°C for at least 15 minutes; and

(b) lysing said necrotic tumor cells so as to obtain a lysate.

51. (New) A lysate obtainable by a process comprising the steps:

(a) inducing necrosis of tumor cells by subjecting the cells to a temperature of more than 41.2°C for more than 2 hours; and

(b) lysing said necrotic tumor cells so as to obtain a lysate.

52. (New) A lysate obtainable by a process comprising the steps:

(a) inducing necrosis of more than one type of tumor cells by subjecting the cells to a temperature of more than 41.2°C for at least 15 minutes; and

(b) lysing said necrotic tumor cells so as to obtain a lysate.

53. (New) A lysate obtainable by a process comprising the steps:

(a) inducing necrosis of NM-F9 or NM-D4 tumor cells by subjecting the cells to a temperature of more than 41.2°C for at least 15 minutes; and

(b) lysing said necrotic tumor cells so as to obtain a lysate.

54. (New) Dendritic cells loaded with the lysate of claim 50-53.

55. (New) A composition comprising the lysate of any one of claims 50-53.

56. (New) A composition comprising the dendritic cells of claim 54.

57. (New) A vaccine comprising the lysate of any one of claims 50-53.

58. (New) A vaccine comprising the dendritic cells of claim 54.

59. (New) The dendritic cells of claim 54, wherein said dendritic cells are immature.

60. (New) The dendritic cells of claim 54, wherein said dendritic cells are mature.

61. (New) The lysate of claims 50-53, wherein necrosis is induced in tumor cells selected from the group consisting of tumor cell lines, cells derived from primary tumor material, cells derived from cell populations of primary tumor material and/or metastases including micrometastases.

62. (New) The dendritic cells of claim 54, wherein necrosis is induced in tumor cells selected from the group consisting of tumor cell lines, cells derived from primary tumor material, cells derived from cell populations of primary tumor material and/or metastases including micrometastases.

63. (New) The lysate of claim 50-53, wherein induction of necrosis is achieved by incubating said tumor cells at a temperature in the range from at least 45.5°C to 55°C.

64. (New) The dendritic cells of claim 54, wherein induction of necrosis is achieved by incubating said tumor cells at a temperature in the range from at least 45.5°C to 55°C.

65. (New) The lysate of claim 50-53, wherein induction of necrosis is achieved by incubating said tumor cells at a temperature in the range of 45.5°C to 47°C.

66. (New) The dendritic cells of claim 54, wherein induction of necrosis is achieved by incubating said tumor cells at a temperature in the range of 45.5°C to 47°C.

67. (New) The lysate of claim 50-53, wherein the induction of necrosis is performed in the range of more than 2 hours to 3 hours.

68. (New) The dendritic cells of claim 54, wherein the induction of necrosis is performed in the range of more than 2 hours to 3 hours.

69. (New) The lysate of claims 50-53, wherein more than 40% of the tumor cells are necrotic after induction of necrosis.

70. (New) The dendritic cells of claim 54, wherein more than 40% of the tumor cells are necrotic after induction of necrosis.

71. (New) The lysate of claims 50-53, wherein more than 70% of the tumor cells are necrotic after induction of necrosis.

72. (New) The dendritic cells of claim 54, wherein more than 70% of the tumor cells are necrotic after induction of necrosis.

73. (New) The lysate of claims 50-53, wherein the tumor cells are genetically engineered, mutated or infected by oncogenic viruses.

74. (New) The dendritic cells of claim 54, wherein the tumor cells are genetically engineered, mutated or infected by oncogenic viruses.

75. (New) The lysate of claim 50-53, wherein the tumor cells are autologous to the subject to be treated.

76. (New) The lysate of claim 50-53, wherein the tumor cells are allogenic to the subject to be treated.

77. (New) The lysate of claim 50-53, wherein the tumor cells are syngenic to the subject to be treated.

78. (New) The lysate of claim 50-53, wherein the tumor cells are xenogenic to the subject to be treated.

79. (New) The lysate of claim 52, wherein the tumor cells are from the same or different individuals, tissues, cell types or tumors.

80. (New) Dendritic cells loaded with the lysate of claim 52, wherein the tumor cells are from the same or different individuals, tissues, cell types or tumors.